Dermatology Unit, Hospital Universitario San Cecilio, Granada, Spain.
Dermatology Unit, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
Dermatol Ther. 2019 Jul;32(4):e12931. doi: 10.1111/dth.12931. Epub 2019 Apr 25.
Atopic dermatitis (AD) is a chronic, systemic disease that has a multifactorial etiology, where immune system disorders and epidermal barrier dysfunction are added to the influence of genetic and environmental factors. Dupilumab has been approved by United States and the European Union regulatory agencies in 2017 for the treatment of moderate-to-severe AD in adult patients who are candidates for systemic treatment. In this short report, we present a retrospective, multicentric study, in which five hospitals in Andalusia, Spain, have taken part. Our objective is to evaluate the safety and effectiveness of dupilumab in patients with moderate-to-severe AD treated with dupilumab with at least 52 weeks of follow-up.
特应性皮炎（AD）是一种慢性全身性疾病，其病因具有多因素性，除了遗传和环境因素外，还存在免疫系统紊乱和表皮屏障功能障碍。2017 年，dupilumab 被美国和欧盟监管机构批准用于治疗适合全身治疗的中重度 AD 成年患者。在这份简短的报告中，我们介绍了一项回顾性、多中心研究，该研究由西班牙安达卢西亚的五家医院参与。我们的目的是评估至少随访 52 周的中重度 AD 患者接受 dupilumab 治疗的安全性和有效性。
